Alteogen Inc

KR

Health Care

166300 ₽

Current price

Strong sell
166300 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    601 / 1361

  • Position in country

    2023 / 2780

  • Return on Assets, %

    -1.5

    -40.3

  • Net income margin, %

    -59.8

    -180

  • EBITDA margin, %

    -32.2

    -168.2

  • Debt to Equity, %

    56.5

    3.2

  • Intangible assets and goodwill, %

    34.8

    0.2

  • Revenue CAGR 3Y, %

    31.5

    12.5

  • Total Equity change 1Y, %

    -3.1

    -9

  • Revenue Y, % chg

    227.9

    0

  • P/BV

    63.9

    1.8

  • P/S

    98.1

    10.3

  • EV/S

    97.8

    7.5

  • EV/EBITDA

    -816.3

    -1.6

  • Average Analyst recommendation

    Buy

    Buy

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • PharmaResearch Co Ltd

    00%

  • Hugel Inc

    00%

  • Amgen Inc

    00%

  • Celltrion Inc

    00%

  • Seegene Inc

    00%

  • Alteogen Inc

    00%

  • GC Biopharma Corp

    00%

  • ABL Bio Inc

    00%

  • AbbVie Inc

    00%

  • SK Bioscience Co Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Korea; Republic (S. Korea)

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    6929.8

  • Ticker

    196170.KQ

  • ISIN

    KR7196170005

  • IPO date

    2014-12-12

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-03-18

  • Date fact. publication of reports

    2023-12-31

Company Description

Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.